Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Mechanisms Of Immune Escape In The Cancer Immune Cycle.

S. Tang, Q. Ning, L. Yang, Zhong-cheng Mo, S. Tang
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer is a critical issue globally with high incidence and mortality, imposing great burden on the society. Although great progress has been made in immunotherapy based on immune checkpoint, only a subset of patients responds to this treatment, suggesting that cancer immune evasion is still a major barrier in current immunotherapy. There are a series of factors contributing to immune evasion despite in an immunocompetent environment. Given that these factors are involved in different steps of the cancer immune cycle. In this review, we discuss the mechanisms of immune escape in each step of the cancer immune cycle and then present therapeutic strategies for overcoming immune escape, with the potential to better understand the determinants of immune escape and make anti-tumor immunity more effective.
This paper references
10.1002/ijc.31661
Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman (2018)
10.1200/JCO.18.01042
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
N. Ready (2019)
10.20892/J.ISSN.2095-3941.2018.0306
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Y. Que (2019)
10.1200/JCO.2018.78.9602
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
T. Mitchell (2018)
10.1038/s41568-019-0116-x
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
J. Havel (2019)
10.1038/ncomms12624
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
J. Wallin (2016)
10.1158/2159-8290.CD-18-0367
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
S. Wei (2018)
10.1038/s41590-019-0512-0
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
L. Andrews (2019)
10.1038/nm.3541
Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors
Gregory T. Motz (2014)
10.1038/nri1845
Dendritic cells in a mature age
C. R. E. Sousa (2006)
10.1158/1078-0432.CCR-18-0762
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
A. Sharma (2018)
10.1158/2326-6066.CIR-18-0683
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Carino Gurjao (2019)
10.1016/j.celrep.2015.08.077
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Rikke B. Holmgaard (2015)
10.1038/s41571-019-0175-7
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Yosuke Togashi (2019)
10.1038/nature23003
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U. Sahin (2017)
10.1016/j.ccell.2018.03.018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
M. Hellmann (2018)
10.1111/imm.13001
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
10.1136/gutjnl-2018-316324
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer
C. Lin (2019)
10.1016/j.cell.2017.01.017
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
P. Sharma (2017)
10.1038/s41573-019-0041-4
Next-generation regulatory T cell therapy
Leonardo M. R. Ferreira (2019)
10.1038/nature18945
Neoantigen landscape dynamics during human melanoma–T cell interactions
E. Verdegaal (2016)
10.1080/2162402X.2016.1274476
Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition
Yosuke Shionoya (2017)
10.1038/s41571-018-0142-8
Cancer immunoediting and resistance to T cell-based immunotherapy
J. S. O’Donnell (2018)
10.1016/j.ccell.2018.04.001
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
M. Hellmann (2018)
10.3390/ijms21020597
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
K. Kunimasa (2020)
10.1038/s41590-018-0132-0
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Q. Zhang (2018)
10.1080/2162402X.2016.1249561
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
R. Huang (2017)
10.1056/NEJMRA1514296
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
V. Boussiotis (2016)
10.4049/jimmunol.1701019
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
S. Ostrand-Rosenberg (2018)
10.1016/j.celrep.2017.07.075
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.
M. Gato-Cañas (2017)
10.1016/j.canlet.2018.05.005
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Ai-lin Li (2018)
10.1056/NEJMoa1709866
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
Shannon L Maude (2018)
10.1158/0008-5472.CAN-18-0668
IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.
K. Bishnupuri (2019)
10.1158/1078-0432.CCR-15-0357
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
K. Kurose (2015)
10.1111/imr.12525
Immunoregulatory functions of VISTA
Elizabeth Nowak (2017)
10.3892/ol.2019.10855
TIM-3 expression and its association with overall survival in primary osteosarcoma
Feifei Pu (2019)
10.1038/nrclinonc.2018.29
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D. Fukumura (2018)
10.1038/s41422-018-0011-0
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du (2018)
10.1002/stem.2780
Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion
Mohammad Sultan (2018)
10.1016/j.smim.2019.101302
Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance.
R. Tang (2019)
10.1158/0008-5472.CAN-19-2254
Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer
Baoying Hu (2020)
10.1038/ncomms10501
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama (2016)
10.1158/1078-0432.CCR-17-2337
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
S. E. Josefsson (2017)
10.1182/blood-2017-07-796342
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
F. Vari (2018)
10.1186/s40425-018-0403-1
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
Yasuko Tada (2018)
10.3389/fimmu.2018.00398
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming (2018)
10.1080/2162402X.2017.1356143
TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer
Agnes Ling (2017)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
10.1038/nature22991
An immunogenic personal neoantigen vaccine for patients with melanoma
P. Ott (2017)
10.1158/1078-0432.CCR-18-0330
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients
M. Kobayashi (2018)
10.1016/j.cell.2019.01.021
VEGF in Signaling and Disease: Beyond Discovery and Development
R. Apte (2019)
10.1038/nrd.2018.169
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta (2018)
10.1186/s13046-018-0713-7
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
J. Liu (2018)
10.1016/j.jid.2017.03.033
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
S. H. Kim (2017)
10.1111/nyas.14039
Knockdown of endothelin receptor B inhibits the progression of triple‐negative breast cancer
X. Gu (2019)
10.1056/NEJMra1703481
Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade
M. Postow (2018)
10.1126/science.aar4060
Cancer immunotherapy using checkpoint blockade
A. Ribas (2018)
10.1158/2159-8290.CD-16-0828
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
V. Anagnostou (2017)
10.1111/imr.12519
LAG3 (CD223) as a cancer immunotherapy target
L. Andrews (2017)
10.1056/nejmoa1910549
Pembrolizumab for Early Triple-Negative Breast Cancer.
P. Schmid (2020)
10.1016/j.imlet.2018.05.002
Tumor exosomes block dendritic cells maturation to decrease the T cell immune response.
Yongling Ning (2018)
10.1038/s41467-017-02186-9
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
F. Veglia (2017)
10.1182/blood-2007-11-123141
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
T. Azuma (2008)
10.1056/NEJMra1706169
Chimeric Antigen Receptor Therapy.
C. June (2018)
10.1016/j.immuni.2016.05.001
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
A. Anderson (2016)
10.1038/nrclinonc.2016.58
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros (2016)
10.1016/j.cyto.2018.03.008
Interleukin 35: Inhibitory regulator in monocyte‐derived dendritic cell maturation and activation
X. Chen (2018)
10.1038/nri.2017.131
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu (2018)
10.1172/JCI60083
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
D. Vasquez-Dunddel (2013)
10.1038/s41586-019-1674-5
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston (2019)
10.1016/S1470-2045(15)70122-1
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont (2015)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1016/j.canlet.2017.12.032
T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
P. Di Gennaro (2018)
10.1016/j.tips.2017.11.007
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Jae Eun Cheong (2018)
10.1016/J.IMMUNI.2005.03.013
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
David H. Munn (2005)
10.1007/s11060-015-2017-5
Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas
S. Nakashima (2015)
10.1007/s00262-018-2169-1
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
10.1007/s00262-015-1791-4
IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells
Yosuke Ohno (2015)
10.1080/2162402X.2018.1469594
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
10.1016/j.immuni.2018.03.014
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun (2018)
10.1158/1535-7163.MCT-18-0836
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Srimoyee Ghosh (2018)
10.1016/j.gene.2017.09.010
CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
L. Shi (2017)
10.1158/1078-0432.CCR-18-2740
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
K. Jung (2019)
10.1158/1078-0432.CCR-17-2852
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
K. Yonesaka (2018)
10.1186/s13046-019-1259-z
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte (2019)
10.1038/s41467-017-01062-w
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman (2017)
10.1038/nm1699
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
R. Buckanovich (2008)
10.1016/j.canlet.2019.05.003
Treg-mediated acquired resistance to immune checkpoint inhibitors.
R. Saleh (2019)
10.1111/cas.13332
Interleukin‐6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy
H. Kitamura (2017)
10.1158/1078-0432.CCR-15-2626
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Y. Kong (2016)
10.1080/2162402X.2018.1466769
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
A. Hung (2018)
10.1084/jem.20140559
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
T. Voron (2015)
10.1158/1535-7163.MCT-18-1376
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
E. Burova (2019)
10.1073/pnas.1612920114
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
V. Prima (2017)
10.1172/JCI81187
TIGIT predominantly regulates the immune response via regulatory T cells.
S. Kurtuluş (2015)
10.1126/science.aaf1490
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N. McGranahan (2016)
10.1111/imcb.1003
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Varun Sasidharan Nair (2018)
10.1111/cas.13723
PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
M. Nakano (2018)
10.1056/NEJMoa1707447
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma
S. Neelapu (2017)
10.1200/JCO.2014.56.2736
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
10.1158/0008-5472.CAN-13-3723
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Y. Zhu (2014)
10.1038/nrc.2016.154
Targeting neoantigens to augment antitumour immunity
M. Yarchoan (2017)
10.1002/ijc.32024
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
Takuma Matoba (2019)
10.1158/0008-5472.CAN-17-0381
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
W. He (2017)
10.1159/000490025
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
10.3892/ol.2018.9743
The effects of Tim-3 activation on T-cells in gastric cancer progression
J. Yu (2019)
10.1007/s00262-018-2175-3
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Y. Liu (2018)
10.1016/j.cellimm.2019.104008
B7-H4, a promising target for immunotherapy.
J. Wang (2019)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1158/1078-0432.CCR-14-1860
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
G. Beatty (2014)
10.1200/JCO.2010.32.2537
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
P. Robbins (2011)
10.1056/NEJMoa1504030
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
10.1038/s41577-019-0224-6
TIM3 comes of age as an inhibitory receptor
Y. Wolf (2019)
10.1056/NEJMoa1604958
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M. Zaretsky (2016)
10.1016/j.cell.2018.11.010
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
J. Wang (2019)
10.1016/j.trecan.2017.11.005
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
G. Prendergast (2018)
10.1038/s41416-018-0313-5
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
10.3389/fimmu.2019.01594
The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
I. Yasinska (2019)
10.1158/2326-6066.CIR-18-0725
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
L. Wu (2019)
10.1126/scitranslmed.aah3560
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh (2017)
10.1038/ni.3540
An essential role for IL-2 receptor in regulatory T cell function
T. Chinen (2016)
10.1172/JCI90499
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Nicholas A. Taylor (2017)
10.1080/2162402X.2019.1674605
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm (2019)
10.1093/annonc/mdx557
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
S. Burugu (2017)
10.1158/2159-8290.CD-17-0593
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
S. Gettinger (2017)
10.1158/2326-6066.CIR-18-0419
Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape
Fatima Ahmetlić (2019)
10.1038/nrclinonc.2016.217
Tumour-associated macrophages as treatment targets in oncology
A. Mantovani (2017)
10.1016/j.immuni.2013.07.012
Oncology meets immunology: the cancer-immunity cycle.
D. Chen (2013)
10.1007/s00262-018-2246-5
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L Solomon (2018)
10.1186/s40425-019-0562-8
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
G. Gibney (2019)
10.1038/nri.2017.108
The diverse functions of the PD1 inhibitory pathway
A. Sharpe (2018)
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.
A. Dirkx (2003)
10.1038/s41598-018-21856-2
Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice
Min-Jung Park (2018)
10.1016/j.ccell.2018.02.005
Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation.
Y. Liu (2018)
10.1038/s41585-020-0282-3
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu (2020)
10.1016/j.clim.2017.08.021
CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.
Mengjie Wang (2018)
10.1038/nrclinonc.2018.9
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan (2018)
10.1016/j.cellimm.2019.103958
TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
X. Zhang (2019)
10.1016/j.coi.2014.01.004
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
D. Mittal (2014)
10.1038/s41573-019-0016-5
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
M. Platten (2019)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar